Why the study?
The impact of T2DM on functional capacity assessed by the 6-min step test and its role as a prognostic marker for fatal and non-fatal events in CHF were unknown.
Does the presence of Type 2 Diabetes Mellitus reduce functional capacity and increase adverse clinical events in patients with chronic heart failure?
Does the presence of Type 2 Diabetes Mellitus reduce functional capacity and increase adverse clinical events in patients with chronic heart failure?
The coexistence of type 2 diabetes mellitus in patients with chronic heart failure significantly impairs functional capacity as measured by the 6-minute step test and is associated with increased 3-year mortality and myocardial infarction risk.
T2DM may worsen 6MST performance in CHF; leaves open independent prognostic value for events.
BACKGROUND: Type 2 diabetes mellitus (T2DM) and chronic heart failure (CHF) present a decrease in functional capacity due to the intrinsic nature of both pathologies. It is not known about the potential impact of T2DM on functional capacity when assessed by 6-min step test (6MST) and its effect as a prognostic marker for fatal and non-fatal events in patients with CHF. OBJECTIVE: to evaluate the coexistence of T2DM and CHF in functional capacity through 6MST when compared to CHF non-T2DM, as well as to investigate the different cardiovascular responses to 6MST and the risk of mortality, decompensation of CHF and acute myocardial infarction (AMI) over 36 months. METHODS: This is a prospective cohort study with 36 months of follow-up in individuals with T2DM and CHF. All participants completed a clinical assessment, followed by pulmonary function testing, echocardiography, and 6MST. The 6MST was performed on a 20 cm high step and cardiovascular responses were collected: heart rate, systemic blood pressure, oxygen saturation, BORG dyspnea and fatigue. The risk of mortality, acute myocardial infarction and decompensation of CHF was evaluated. RESULTS: Eighty-six participants were included. The CHF-T2DM group had a significantly lower functional capacity than the CHF non-T2DM group (p < 0.05). Forced Expiratory Volume in one second (L), ejection fraction (%), gender and T2DM influence and are predictors of functional capacity (p < 0.05; adjusted R squared: 0.419). CHF-T2DM group presented a higher risk of mortality and acute myocardial infarction over the 36 months of follow-up (p < 0.05), but not to the risk of decompensation (p > 0.05). CONCLUSION: T2DM negatively affects the functional performance of 6MST in patients with CHF. Gender, ejection fraction (%), FEV1 (L) and T2DM itself negatively influence exercise performance.
No takes yet. Share an insight, caveat, or question.
Santos‐de‐Araújo et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: